糖尿病性眼疾患 - 市場考察、疫学、市場予測（2034年）

当レポートでは、糖尿病性眼疾患の主要7市場（米国、ドイツ、スペイン、イタリア、フランス、英国、日本）について調査分析し、各地域の市場規模、現在の治療法、アンメットニーズ、新治療法などの情報を提供しています。

目次

第1章 重要考察

第2章 糖尿病性眼疾患のエグゼクティブサマリー

第3章 糖尿病性眼疾患に関する競合情報分析

第4章 糖尿病性眼疾患：市場の概要

• 糖尿病性眼疾患の総市場シェアの分布（2020年）
• 糖尿病性眼疾患の総市場シェアの分布（2034年）

第5章 糖尿病性眼疾患：疾患の背景と概要

• イントロダクション
• 兆候と症状
• 病態生理学
• 危険因子
• 診断

第6章 ペイシェントジャーニー

第7章 糖尿病性眼疾患の疫学と患者人口

• 疫学の主な調査結果
• 前提条件と根拠：主要7市場
• 疫学シナリオ：主要7市場
  • 主要7市場の糖尿病性眼疾患の疫学シナリオ（2020年～2034年）
• 米国の疫学
  • 米国の糖尿病性眼疾患の疫学シナリオ（2020年～2034年）
• 欧州5ヶ国の疫学：国別
  • ドイツの疫学
  • フランスの疫学
  • イタリアの疫学
  • スペインの疫学
  • 英国の疫学
  • 日本の疫学

第8章 治療アルゴリズム、現在の治療、医療行為

• 糖尿病性眼疾患の治療と管理
• 糖尿病性眼疾患の治療アルゴリズム

第9章 アンメットニーズ

第10章 糖尿病性眼疾患治療の主要評価項目

第11章 上市済みの製品

第12章 新治療法

第13章 糖尿病性眼疾患：主要7市場の分析

• 主な調査結果
• 主要7市場の糖尿病性眼疾患の市場規模
• 主要7市場の糖尿病性眼疾患の市場規模：治療法別

第14章 属性分析

第15章 主要7市場：市場見通し

• 米国：市場規模
  • 米国の糖尿病性眼疾患の総市場規模
  • 米国の糖尿病性眼疾患の市場規模：治療法別
• 欧州5ヶ国：市場規模と見通し
• ドイツの市場規模
  • ドイツの糖尿病性眼疾患の総市場規模
  • ドイツの糖尿病性眼疾患の市場規模：治療法別
• フランスの市場規模
• イタリアの市場規模
• スペインの市場規模
• 英国の市場規模
  • 英国の糖尿病性眼疾患の総市場規模
  • 英国の糖尿病性眼疾患の市場規模：治療法別
• 日本市場の見通し
  • 日本の市場規模

第16章 糖尿病性眼疾患のアクセスと償還の概要

第17章 KOLの見解

第18章 市場促進要因

第19章 市場の障壁

第20章 付録

第21章 DelveInsightのサービス内容

第22章 免責事項

第23章 DelveInsightについて

List of Tables

• Table 1: 7MM Diabetic Eye Disease Epidemiology (2020-2034)
• Table 2: 7MM Diabetic Eye Disease Diagnosed and Treatable Cases (2020-2034)
• Table 3: Diabetic Eye Disease Epidemiology in the United States (2020-2034)
• Table 4: Diabetic Eye Disease Diagnosed and Treatable Cases in the United States (2020-2034)
• Table 5: Diabetic Eye Disease Epidemiology in Germany (2020-2034)
• Table 6: Diabetic Eye Disease Diagnosed and Treatable Cases in Germany (2020-2034)
• Table 7: Diabetic Eye Disease Epidemiology in France (2020-2034)
• Table 8: Diabetic Eye Disease Diagnosed and Treatable Cases in France (2020-2034)
• Table 9: Diabetic Eye Disease Epidemiology in Italy (2020-2034)
• Table 10: Diabetic Eye Disease Diagnosed and Treatable Cases in Italy (2020-2034)
• Table 11: Diabetic Eye Disease Epidemiology in Spain (2020-2034)
• Table 12: Diabetic Eye Disease Diagnosed and Treatable Cases in Spain (2020-2034)
• Table 13: Diabetic Eye Disease Epidemiology in the UK (2020-2034)
• Table 14: Diabetic Eye Disease Diagnosed and Treatable Cases in the UK (2020-2034)
• Table 15: Diabetic Eye Disease Epidemiology in Japan (2020-2034)
• Table 16: Diabetic Eye Disease Diagnosed and Treatable Cases in Japan (2020-2034)
• Table 17: Drug Name, Clinical Trials by Recruitment status
• Table 18: Drug Name, Clinical Trials by Zone
• Table 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Table 20: Region-wise Market Size in USD, Million (2020-2034)
• Table 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Table 22: United States Market Size in USD, Million (2020-2034)
• Table 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Table 24: Germany Market Size in USD, Million (2020-2034)
• Table 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Table 26: France Market Size in USD, Million (2020-2034)
• Table 27: France Market Size by Therapy in USD, Million (2020-2034)
• Table 28: Italy Market Size in USD, Million (2020-2034)
• Table 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Table 30: Spain Market Size in USD, Million (2020-2034)
• Table 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Table 32: United Kingdom Market Size in USD, Million (2020-2034)
• Table 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Table 34: Japan Market Size in USD, Million (2020-2034)
• Table 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of tables is not exhaustive; the final content may vary

List of Figures

• Figure 1: 7MM Diabetic Eye Disease Epidemiology (2020-2034)
• Figure 2: 7MM Diabetic Eye Disease Diagnosed and Treatable Cases (2020-2034)
• Figure 3: Diabetic Eye Disease Epidemiology in the United States (2020-2034)
• Figure 4: Diabetic Eye Disease Diagnosed and Treatable Cases in the United States (2020-2034)
• Figure 5: Diabetic Eye Disease Epidemiology in Germany (2020-2034)
• Figure 6: Diabetic Eye Disease Diagnosed and Treatable Cases in Germany (2020-2034)
• Figure 7: Diabetic Eye Disease Epidemiology in France (2020-2034)
• Figure 8: Diabetic Eye Disease Diagnosed and Treatable Cases in France (2020-2034)
• Figure 9: Diabetic Eye Disease Epidemiology in Italy (2020-2034)
• Figure 10: Diabetic Eye Disease Diagnosed and Treatable Cases in Italy (2020-2034)
• Figure 11: Diabetic Eye Disease Epidemiology in Spain (2020-2034)
• Figure 12: Diabetic Eye Disease Diagnosed and Treatable Cases in Spain (2020-2034)
• Figure 13: Diabetic Eye Disease Epidemiology in the UK (2020-2034)
• Figure 14: Diabetic Eye Disease Diagnosed and Treatable Cases in the UK (2020-2034)
• Figure 15: Diabetic Eye Disease Epidemiology in Japan (2020-2034)
• Figure 16: Diabetic Eye Disease Diagnosed and Treatable Cases in Japan (2020-2034)
• Figure 17: Drug Name, Clinical Trials by Recruitment status
• Figure 18: Drug Name, Clinical Trials by Zone
• Figure 19: Total Seven Major Market Size in USD, Million (2020-2034)
• Figure 20: Region-wise Market Size in USD, Million (2020-2034)
• Figure 21: 7MM-Market Size by Therapy in USD, Million (2020-2034)
• Figure 22: United States Market Size in USD, Million (2020-2034)
• Figure 23: United States Market Size by Therapy in USD, Million (2020-2034)
• Figure 24: Germany Market Size in USD, Million (2020-2034)
• Figure 25: Germany Market Size by Therapy in USD, Million (2020-2034)
• Figure 26: France Market Size in USD, Million (2020-2034)
• Figure 27: France Market Size by Therapy in USD, Million (2020-2034)
• Figure 28: Italy Market Size in USD, Million (2020-2034)
• Figure 29: Italy Market Size by Therapy in USD, Million (2020-2034)
• Figure 30: Spain Market Size in USD, Million (2020-2034)
• Figure 31: Spain Market Size by Therapy in USD, Million (2020-2034)
• Figure 32: United Kingdom Market Size in USD, Million (2020-2034)
• Figure 33: United Kingdom Market Size by Therapy in USD, Million (2020-2034)
• Figure 34: Japan Market Size in USD, Million (2020-2034)
• Figure 35: Japan Market Size by Therapy in USD, Million (2020-2034)

The list of figures is not exhaustive; the final content may vary

DelveInsight's "Diabetic Eye Disease - Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Diabetic Eye Disease, historical and forecasted epidemiology as well as the Diabetic Eye Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Diabetic Eye Disease market report provides current treatment practices, emerging drugs, Diabetic Eye Disease market share of the individual therapies, current and forecasted Diabetic Eye Disease market size from 2020 to 2034 segmented by seven major markets. The Report also covers current Diabetic Eye Disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Geography Covered:

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2020-2034

Diabetic Eye Disease Disease Understanding and Treatment Algorithm

The DelveInsight Diabetic Eye Disease market report gives a thorough understanding of the Diabetic Eye Disease by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment.

Diagnosis

This segment of the report covers the detailed diagnostic methods or tests for Diabetic Eye Disease.

Treatment

It covers the details of conventional and current medical therapies available in the Diabetic Eye Disease market for the treatment of the condition. It also provides Diabetic Eye Disease treatment algorithms and guidelines in the United States, Europe, and Japan.

Diabetic Eye Disease Epidemiology

The Diabetic Eye Disease epidemiology division provide insights about historical and current Diabetic Eye Disease patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Diabetic Eye Disease epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2020 to 2034.

Country Wise-Diabetic Eye Disease Epidemiology

The epidemiology segment also provides the Diabetic Eye Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Diabetic Eye Disease Drug Chapters

Drug chapter segment of the Diabetic Eye Disease report encloses the detailed analysis of Diabetic Eye Disease marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Diabetic Eye Disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Marketed Drugs

The report provides the details of the marketed product available for Diabetic Eye Disease treatment.

Diabetic Eye Disease Emerging Drugs

The report provides the details of the emerging therapies under the late and mid-stage of development for Diabetic Eye Disease treatment.

Diabetic Eye Disease Market Outlook

The Diabetic Eye Disease market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Diabetic Eye Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a thorough detail of Diabetic Eye Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Diabetic Eye Disease market in 7MM is expected to change in the study period 2020-2034.

Key Findings

This section includes a glimpse of the Diabetic Eye Disease market in 7MM.

The United States Market Outlook

This section provides the total Diabetic Eye Disease market size and market size by therapies in the United States.

EU-5 Countries: Market Outlook

The total Diabetic Eye Disease market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Market Outlook

The total Diabetic Eye Disease market size and market size by therapies in Japan is also mentioned.

Diabetic Eye Disease Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the Diabetic Eye Disease market or expected to get launched in the market during the study period 2020-2034. The analysis covers Diabetic Eye Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Diabetic Eye Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Diabetic Eye Disease key players involved in developing targeted therapeutics.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details and other information for Diabetic Eye Disease emerging therapies.

Reimbursement Scenario in Diabetic Eye Disease

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

KOL- Views

To keep up with current market trends, we take KOLs and SME's opinion working in Diabetic Eye Disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Diabetic Eye Disease market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Diabetic Eye Disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

• The report covers the descriptive overview of Diabetic Eye Disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Diabetic Eye Disease epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Diabetic Eye Disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
• A detailed review of Diabetic Eye Disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Diabetic Eye Disease market

Report Highlights:

• In the coming years, Diabetic Eye Disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Diabetic Eye Disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
• Major players are involved in developing therapies for Diabetic Eye Disease. Launch of emerging therapies will significantly impact the Diabetic Eye Disease market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Diabetic Eye Disease
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Diabetic Eye Disease Report Insights

• Patient Population
• Therapeutic Approaches
• Diabetic Eye Disease Pipeline Analysis
• Diabetic Eye Disease Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Diabetic Eye Disease Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Diabetic Eye Disease Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Diabetic Eye Disease Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Market Drivers and Barriers

Key Questions:

Market Insights:

• What was the Diabetic Eye Disease market share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Diabetic Eye Disease total market size as well as market size by therapies across the 7MM during the forecast period (2024-2034)?
• What are the key findings pertaining to the market across 7MM and which country will have the largest Diabetic Eye Disease market size during the forecast period (2024-2034)?
• At what CAGR, the Diabetic Eye Disease market is expected to grow in 7MM during the forecast period (2020-2034)?
• What would be the Diabetic Eye Disease market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Diabetic Eye Disease market growth till 2032, and what will be the resultant market Size in the year 2034?
• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of the Diabetic Eye Disease?
• What is the historical Diabetic Eye Disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Diabetic Eye Disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Diabetic Eye Disease?
• Out of all 7MM countries, which country would have the highest prevalent population of Diabetic Eye Disease during the forecast period (2020-2034)?
• At what CAGR the population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Diabetic Eye Disease treatment, along with the approved therapy?
• What are the current treatment guidelines for the treatment of Diabetic Eye Disease in the USA, Europe, and Japan?
• What are the Diabetic Eye Disease marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many companies are developing therapies for the treatment of Diabetic Eye Disease?
• How many therapies are developed by each company for Diabetic Eye Disease treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Diabetic Eye Disease treatment?
• What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Diabetic Eye Disease therapies?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diabetic Eye Disease and their status?
• What are the key designations that have been granted for the emerging therapies for Diabetic Eye Disease?
• What are the global historical and forecasted market of Diabetic Eye Disease?

Reasons to buy:

• The report will help in developing business strategies by understanding trends shaping and driving the Diabetic Eye Disease market
• To understand the future market competition in the Diabetic Eye Disease market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Diabetic Eye Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Diabetic Eye Disease market
• To understand the future market competition in the Diabetic Eye Disease market

Table of Contents

1. Key Insights

2. Executive Summary of Diabetic Eye Disease

3. Competitive Intelligence Analysis for Diabetic Eye Disease

4. Diabetic Eye Disease: Market Overview at a Glance

• 4.1. Diabetic Eye Disease Total Market Share (%) Distribution in 2020
• 4.2. Diabetic Eye Disease Total Market Share (%) Distribution in 2034

5. Diabetic Eye Disease: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Diabetic Eye Disease Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Diabetic Eye Disease Epidemiology Scenario in the 7MM (2020-2034)
• 7.4. United States Epidemiology
  • 7.4.1. Diabetic Eye Disease Epidemiology Scenario in the United States (2020-2034)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Diabetic Eye Disease Epidemiology Scenario in Germany (2020-2034)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Diabetic Eye Disease Epidemiology Scenario in France (2020-2034)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Diabetic Eye Disease Epidemiology Scenario in Italy (2020-2034)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Diabetic Eye Disease Epidemiology Scenario in Spain (2020-2034)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Diabetic Eye Disease Epidemiology Scenario in the United Kingdom (2020-2034)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Diabetic Eye Disease Epidemiology Scenario in Japan (2020-2034)

8. Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Diabetic Eye Disease Treatment and Management
• 8.2. Diabetic Eye Disease Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Diabetic Eye Disease Treatment

11. Marketed Products

• 11.1. List of Marketed Products in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

List to be continued in report

13. Diabetic Eye Disease: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Diabetic Eye Disease Market Size in 7MM
• 13.3. Diabetic Eye Disease Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States: Market Size
  • 15.1.1. Diabetic Eye Disease Total Market Size in the United States
  • 15.1.2. Diabetic Eye Disease Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Market Size
  • 15.3.1. Diabetic Eye Disease Total Market Size in Germany
  • 15.3.2. Diabetic Eye Disease Market Size by Therapies in Germany
• 15.4. France Market Size
  • 15.4.1. Diabetic Eye Disease Total Market Size in France
  • 15.4.2. Diabetic Eye Disease Market Size by Therapies in France
• 15.5. Italy Market Size
  • 15.5.1. Diabetic Eye Disease Total Market Size in Italy
  • 15.5.2. Diabetic Eye Disease Market Size by Therapies in Italy
• 15.6. Spain Market Size
  • 15.6.1. Diabetic Eye Disease Total Market Size in Spain
  • 15.6.2. Diabetic Eye Disease Market Size by Therapies in Spain
• 15.7. United Kingdom Market Size
  • 15.7.1. Diabetic Eye Disease Total Market Size in the United Kingdom
  • 15.7.2. Diabetic Eye Disease Market Size by Therapies in the United Kingdom
• 15.8. Japan Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Diabetic Eye Disease Total Market Size in Japan
  • 15.8.3. Diabetic Eye Disease Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Diabetic Eye Disease

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.